Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 1.00 |
| ▸ | BCHE | P06276 | 16/20 | 0.70 |
| ▸ | ACHE | P22303 | 3/20 | 0.66 |
| ▸ | SNCA | P37840 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30198410 | 1.00 | NOX1 (1.00) | NOX1BCHEACHESNCAPOLB | |
| SCHEMBL19229613 | 0.86 | NOX1 (0.76) | NOX1BCHEACHESNCAPOLB | |
| SCHEMBL9658712 | 0.85 | NOX1 (0.73) | NOX1BCHEACHESNCAPOLB | |
| SCHEMBL17297109 | 0.85 | NOX1 (0.73) | NOX1BCHEACHESNCAPOLB | |
| SCHEMBL30725912 | 0.85 | NOX1 (0.73) | NOX1BCHEACHESNCAGAA | |
| SCHEMBL8870414 | 0.85 | NOX1 (0.73) | NOX1BCHEACHESNCAMAPT | |
| SCHEMBL4622014 | 0.85 | NOX1 (0.73) | NOX1BCHEACHESNCAGAA | |
| SCHEMBL19237052 | 0.85 | NOX1 (0.73) | NOX1BCHEACHESNCAPOLB | |
| SCHEMBL6196289 | 0.83 | NOX1 (0.70) | NOX1BCHEACHESNCAPOLB | |
| SCHEMBL24439550 | 0.83 | NOX1 (0.69) | NOX1BCHEACHESNCAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247165-B2 | Anti-syneresis agents for fracturing operations | HALLIBURTON ENERGY SERVICES, INC. (US) | 2025-03-11 | — | — | US | claimed |
| US-20250051634-A1 | ANTI-SYNERESIS AGENTS FOR FRACTURING OPERATIONS | HALLIBURTON ENERGY SERVICES, INC. (US) | 2025-02-13 | — | — | US | claimed |
| EP-2247687-B1 | COMPOSITIONS AND METHODS OF TREATING HIGH TEMPERATURE SUBTERRANEAN FORMATIONS | BAKER HUGHES A GE CO LLC (US) | 2018-07-25 | — | — | EP | claimed |
| US-9902786-B2 | Method for immediately terminating radical polymerizations, inhibitor solution, and use thereof | ALLESSA GMBH (DE) | 2018-02-27 | — | — | US | claimed |
| US-20170062842-A1 | TWO-ELECTRON REDOX ACTIVE MOLECULES WITH HIGH CAPACITY AND ENERGY DENSITY FOR ENERGY STORAGE APPLICATIONS | UCHICAGO ARGONNE, LLC | 2017-03-02 | — | — | US | claimed |
| EP-2941443-B1 | METHOD FOR IMMEDIATELY TERMINATING RADICAL POLYMERIZATIONS, INHIBITOR SOLUTION, AND USE THEREOF | ALLESSA GMBH (DE) | 2017-02-15 | — | — | EP | claimed |
| EP-2166060-B1 | Stabilized aqueous polymer compositions | TOUGAS OILFIELD SOLUTIONS GMBH (DE) | 2016-08-10 | — | — | EP | claimed |
| EP-2085424-B2 | Stabilized aqueous polymer compositions | TOUGAS OILFIELD SOLUTIONS GMBH (DE) | 2016-01-13 | — | — | EP | claimed |
| US-20150337056-A1 | Method for Immediately Terminating Radical Polymerizations, Inhibitor Solution, and Use Thereof | ALLESSA GMBH (DE) | 2015-11-26 | — | — | US | claimed |
| EP-2941443-A1 | METHOD FOR IMMEDIATELY TERMINATING RADICAL POLYMERIZATIONS, INHIBITOR SOLUTION, AND USE THEREOF | Allessa GmbH (DE) | 2015-11-11 | — | — | EP | claimed |
| EP-1915384-A1 | A METHOD OF MANUFACTURING AN ORGANIC SILICON COMPOUND THAT CONTAINS A METHACRYLOXY GROUP OR AN ACRYLOXY GROUP | Dow Corning Toray Co., Ltd. (JP) | 2008-04-30 | — | — | EP | claimed |
| EP-1883987-A1 | SUBSTITUTED PHENOTHIAZINE REDOX SHUTTLES FOR RECHARGEABLE LITHIUM-ION CELL | 3M Innovative Properties Company (US) | 2008-02-06 | — | — | EP | claimed |
| WO-2007020932-A1 | A METHOD OF MANUFACTURING AN ORGANIC SILICON COMPOUND THAT CONTAINS A METHACRYLOXY GROUP OR AN ACRYLOXY GROUP | DOW CORNING TORAY CO., LTD. (JP) | 2007-02-22 | — | — | WO | claimed |
| US-20060263697-A1 | Substituted phenothiazine redox shuttles for rechargeable lithium-ion cell | 3M INNOVATIVE PROPERTIES COMPANY | 2006-11-23 | — | — | US | claimed |
| WO-2006124738-A1 | SUBSTITUTED PHENOTHIAZINE REDOX SHUTTLES FOR RECHARGEABLE LITHIUM-ION CELL | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-11-23 | — | — | WO | claimed |
| EP-0451675-B1 | Process for the direct and regioselective functionalization in position 2 of phenothiazine | ZAMBON SPA (IT) | 1995-11-02 | — | — | EP | claimed |
| US-5109134-A | PROCESS FOR THE DIRECT AND REGIOSELECTIVE FUNCTIONALIZATION IN POSITION 2 OF PHENOTHIAZINE | ZAMBON GROUP S.P.A. (IT) | 1992-04-28 | — | — | US | claimed |
| US-5089613-A | Sulfonation of N-acylphenothiazine with sulfuric acid, oleum or chlorosulfonic acid then reduciton to mercaptan and S-alkylation | ZAMBON GROUP S.P.A. (IT) | 1992-02-18 | — | — | US | claimed |
| EP-0451675-A1 | Process for the direct and regioselective functionalization in position 2 of phenothiazine | ZAMBON GROUP S.p.A. (IT) | 1991-10-16 | — | — | EP | claimed |
| EP-0433841-A2 | Process for the direct and regioselective functionalization in position 2 of phenotiazine | ZAMBON GROUP S.p.A. (IT) | 1991-06-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170062842-A1 | TWO-ELECTRON REDOX ACTIVE MOLECULES WITH HIGH CAPACITY AND ENERGY DENSITY FOR ENERGY STORAGE APPLICATIONS | CYP11B1, CYP11B2, ESR2 | NOX1 144/4885BCHE 2180/4885ACHE 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.